For research use only. Not for therapeutic Use.
Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-ErbB TKI (Tarlox-TKI)[1].
Epidermal Growth Factor Receptor (EGFR, HER1) is an attractive therapeutic target for many cancer types. Tarlox-TKI is a dose-potent EGFR inhibitor[1].
| Catalog Number | I019515 |
| CAS Number | 2135696-72-7 |
| Synonyms | (E)-N-[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)but-2-enamide |
| Molecular Formula | C19H18BrClN6O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H18BrClN6O/c1-27(2)7-3-4-18(28)26-17-9-13-16(10-22-17)23-11-24-19(13)25-12-5-6-15(21)14(20)8-12/h3-6,8-11H,7H2,1-2H3,(H,22,26,28)(H,23,24,25)/b4-3+ |
| InChIKey | QBACGOWRJDBXSG-ONEGZZNKSA-N |
| SMILES | CN(C)CC=CC(=O)NC1=NC=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)Cl)Br |
| Reference | [1]. Victoria Jackson-Patel, et al. Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies. |
